This series highlights the evolving role of BTK inhibitors for the treatment of CLL.
EP. 2: Jennifer A. Woyach, MD, Reflects on the Changing BTK Inhibitor LandscapeMay 6th 2021
With the treatment landscape rapidly developing with the approval of new agents and the investigation of various combination regimens, understanding the individual profiles of each agent will aid treatment selection.
EP. 6: Exploring the Utility of a Next-Generation BTK Inhibitor for the Treatment of Patients With Chronic Lymphocytic LeukemiaDecember 3rd 2021
Zanubrutinib has demonstrated clinical benefit as both a monotherapy and in combination with other agents for the treatment of patients with chronic lymphocytic leukemia.